1. Home
  2. HCWC vs ICU Comparison

HCWC vs ICU Comparison

Compare HCWC & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HCWC
  • ICU
  • Stock Information
  • Founded
  • HCWC N/A
  • ICU 2018
  • Country
  • HCWC
  • ICU United States
  • Employees
  • HCWC N/A
  • ICU N/A
  • Industry
  • HCWC
  • ICU Biotechnology: Pharmaceutical Preparations
  • Sector
  • HCWC
  • ICU Health Care
  • Exchange
  • HCWC NYSE
  • ICU Nasdaq
  • Market Cap
  • HCWC 11.8M
  • ICU 10.3M
  • IPO Year
  • HCWC N/A
  • ICU N/A
  • Fundamental
  • Price
  • HCWC $0.83
  • ICU $2.00
  • Analyst Decision
  • HCWC
  • ICU
  • Analyst Count
  • HCWC 0
  • ICU 0
  • Target Price
  • HCWC N/A
  • ICU N/A
  • AVG Volume (30 Days)
  • HCWC N/A
  • ICU 24.8K
  • Earning Date
  • HCWC N/A
  • ICU 11-13-2024
  • Dividend Yield
  • HCWC N/A
  • ICU N/A
  • EPS Growth
  • HCWC N/A
  • ICU N/A
  • EPS
  • HCWC N/A
  • ICU N/A
  • Revenue
  • HCWC N/A
  • ICU $68,000.00
  • Revenue This Year
  • HCWC N/A
  • ICU N/A
  • Revenue Next Year
  • HCWC N/A
  • ICU $344.44
  • P/E Ratio
  • HCWC N/A
  • ICU N/A
  • Revenue Growth
  • HCWC N/A
  • ICU N/A
  • 52 Week Low
  • HCWC N/A
  • ICU $1.70
  • 52 Week High
  • HCWC N/A
  • ICU $42.93
  • Technical
  • Relative Strength Index (RSI)
  • HCWC N/A
  • ICU 39.05
  • Support Level
  • HCWC N/A
  • ICU $1.70
  • Resistance Level
  • HCWC N/A
  • ICU $2.04
  • Average True Range (ATR)
  • HCWC 0.00
  • ICU 0.19
  • MACD
  • HCWC 0.00
  • ICU 0.01
  • Stochastic Oscillator
  • HCWC 0.00
  • ICU 33.33

About HCWC HEALTHY CHOICE WELLNESS CORP

Healthy Choice Wellness Corp is a company engaged in providing consumers with healthier daily choices with respect to nutrition and other lifestyle alternatives. The company has one reportable segment which is natural and organic retail stores.

About ICU SeaStar Medical Holding Corporation

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

Share on Social Networks: